Western blotting, immunostaining, and RT‐PCR detected that after 8‐week post ADR injection, all mice developed FSGS by significantly increasing urine albumin excretion, glomerular atrophy, and focal segmental glomerulosclerosis (Figure S1a,b, Supporting Information), and a significant loss of podocyte markers podocin and nephrin (Figure S1c–g, Supporting Information). The gene discussed is NPHS2; the disease is focal segmental glomerulosclerosis.